Kairos Pharma Ltd. (NYSE American: KAPA) announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference, taking place September 28 to October 1 in Boston. The conference is a key event for professionals in drug discovery and development, and Kairos Pharma's participation underscores its commitment to advancing oncology therapeutics.
Bhowmick will moderate a breakout session on September 30 titled "Winning the Race against Cancer Therapy Resistance." This session will focus on Kairos Pharma's strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. The company's approach aims to address a critical challenge in oncology: the ability of cancer cells to develop resistance to standard therapies, leading to relapse and disease progression. By targeting resistance mechanisms, Kairos Pharma hopes to restore the effectiveness of treatments that have stopped working for many patients.
In addition to moderating, Bhowmick will deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern Time on KROS-101, a drug candidate targeting solid tumors. The presentation will highlight KROS-101's mechanism of action, which involves targeting GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This approach represents a novel way to harness the immune system to fight cancer, potentially offering new hope for patients with solid tumors who have limited treatment options.
The significance of this announcement extends beyond the conference itself. Kairos Pharma's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. The company's focus on overcoming drug resistance and immune suppression positions it at the forefront of oncology therapeutics, utilizing structural biology to develop innovative solutions.
For investors and industry observers, Kairos Pharma's presentation at a prestigious conference like Discovery on Target could bring increased visibility and credibility. The event attracts leading researchers, clinicians, and pharmaceutical companies, providing a platform for Kairos Pharma to showcase its science and potentially attract partnerships or investment. The company's progress with KROS-101 and ENV-105 could also have broader implications for cancer treatment, as overcoming resistance remains one of the biggest hurdles in oncology.
Kairos Pharma is based in Los Angeles, California, and its latest news and updates are available in its newsroom. NetworkNewsWire, a specialized communications platform, is covering the announcement. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers, readers can visit the NetworkNewsWire website.
